Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

Despite posting record Q2 growth for its blockbuster weight loss and diabetes drug tirzepatide, Eli Lilly is facing legal ...

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant ...

What Happened: file made a significant move by purchasing 1,565 shares of Eli Lilly as reported in a Form 4 filing with the U.S. Securities and Exchange Commission. The transaction's total worth ...

In a recent SEC filing, it was revealed that David A Ricks, President at Eli Lilly LLY, made a noteworthy insider purchase on August 12,. What Happened: Ricks demonstrated confidence in Eli Lilly by ...

Texas AG Ken Paxton sues Eli Lilly for alleged bribery to promote diabetes drugs, claiming violation of state fraud laws and ...

Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating ...

Patients on Eli Lilly's new oral medication orforglipron lost an average of 12.4% of their body weight over 72 weeks.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Texas Attorney General Ken Paxton claims that through an alleged kickback scheme Eli Lilly “fraudulently sought to maximize profits at taxpayer expense.” ...

Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...

(Reuters) -Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight ...